AI Consensus Investment Thesis
Boston Scientific (BSX) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
No Action - Keep Monitoring
Only one horizon is positive; wait for broader confirmation.
1-Year
NEUTRAL$54
+4.8%5-Year
BUY$91
+77.2%Latest flagship insight
How Underappreciated Demographic Demands Shield Medical Technology Leaders From Macroeconomic Headwinds
High consensus across reports indicates that structural demographic tailwinds and robust free cash flow insulate this medical technology asset from macroeconomic pressures. While competitive entry in electrophysiology poses a primary risk, the core valuation remains deeply discounted relative to its long-term compounding potential.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset presents a highly compelling valuation setup where temporary multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry has decoupled equity pricing from robust, non-discretionary fundamental cash generation. Despite intensifying competitive entry in the pulsed field ablation market and near-term leverage from recent large-scale acquisitions, the core business remains anchored by highly inelastic global cardiovascular demographics and exceptional pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. This structural resilience positions the firm as a premier defensive compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry capable of navigating stagflationary macrostagflationary macroMacroeconomic conditions combining weak growth with persistent inflation.View full glossary entry regimes and delivering consistent operational outperformance.
Key insights
- Inelastic demographic demand for cardiovascular and neurological interventions provides a highly predictable, non-discretionary revenue floor that ignores broader economic cycles.
- Elite gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near seventy percent structurally insulate the enterprise from supply chain bottleneckssupply chain bottlenecksCapacity, material, labor, transport, or coordination constraints that slow the flow of goods and inputs.View full glossary entry, freight inflation, and raw material shocks.
- The strategic integration of recent large-scale acquisitions expands the competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry into high-growth neurovascular and structural heart segments.
- Robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation exceeding three billion dollars annually enables aggressive self-funded capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry, including accelerated share repurchases.
- Valuation multiples have compressed to historically low levels, offering a substantial margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry and asymmetric long-term upside.
- Key operational risks include intensifying electrophysiology price competition from major peers and potential integration delays of serial acquisitions.
- Tight monetary policy acts as a relative tailwind as self-funding capabilities eliminate refinancing risks faced by leveraged competitors.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as a broken growth story experiencing severe multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. The crowd is heavily focused on the sequential stalling of key product lines, particularly in electrophysiology and left atrial appendage closure, following a guidance cut and a massive, debt-funded acquisition. Mainstream analysts and media assume that the loss of the pulsed field ablation monopoly to emerging competitors, combined with potential demand destructiondemand destructionA reduction in demand caused by prices, scarcity, substitution, policy, or weaker economic conditions.View full glossary entry from weight-loss drugs, permanently impairs the company's terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry. Consequently, the crowd treats the transition from hyper-growth to a mature oligopolyoligopolyA market structure dominated by a small number of firms, creating high barriers to entry.View full glossary entry as a fatal franchise collapse, anchoring on short-term integration friction and high interest rates while ignoring the underlying cash flow resilience.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's fundamental mispricing of biological inevitability versus temporary behavioral pharmacology and governance noise. While the crowd fears that weight-loss drugs will eradicate cardiovascular disease, clinical evidence shows that conditions like atrial fibrillation are driven by chronological aging, an inescapable demographic vector. Furthermore, the market is pricing the stock as if competitive entry destroys the franchise, ignoring the company's exceptional cash-conversion physics. At a deeply compressed forward multipleforward multipleForward multiple is a valuation ratio based on forecast earnings, sales, or cash flow rather than historical results.View full glossary entry, the enterprise generates over three billion dollars in free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, allowing it to aggressively buy back shares at distressed levels. The structural blind spot is failing to see that the company has transitioned from a fragile growth story into a highly resilient value compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry with an unassailable pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry moat.
Repricing Catalyst
What could make the market recognize and close that gap? The alpha gapalpha gapA difference between an investment view of potential excess return and the excess return implied by current market expectations.View full glossary entry is expected to close as the company delivers consecutive quarters of stabilized electrophysiology market share and demonstrates seamless integration of its recent large-scale acquisitions. When financial prints show robust, unblemished free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation and margin defense despite global supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry and energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry, the market will be forced to abandon its pessimistic narrative. Additionally, the deployment of massive cash flows into aggressive share repurchases will mechanically accelerate earnings per share, proving the cash engine remains completely intact and forcing institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry to rotate back into this defensive compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Capitulation
While there is broad consensus that the asset has undergone a significant valuation washout, reports diverge on the current cycle position. Some perspectives view the stock as being in a deep capitulation phase following a guidance reset, while others suggest it is in the early discovery stage of a long-term value compounding cycle, reflecting differing horizons on acquisition digestion.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop of sticky stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, elevated interest rates, and geopolitical supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry disruptions presents a mixed setup that ultimately acts as a relative tailwind for the asset. While high capital costs penalize long-duration growth equities and increase debt-servicing friction for recent acquisitions, the company's underlying demand is completely non-discretionary and insulated from consumer spending cycles. With elite gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near seventy percent and a self-funding cash engine, the company bypasses tight credit markets and easily passes through inflationary costs, making it a premier safe haven in a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the strategic wisdom and timing of the company's aggressive, debt-funded acquisitions. Some perspectives view these transactions as highly accretive, generational consolidations that secure dominant moats in high-growth adjacent markets. Conversely, other reports express caution, arguing that taking on significant leverage during a restrictive interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry introduces unnecessary balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry stress and integration distraction that could temporarily depress return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. There is also minor divergence regarding the near-term growth trajectory of legacy product lines.
Base-Case Forces
Event Risk ScoreLow35/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Deep Biological Anchoring | Sector And Industry | +35% | +25% | Global population aging guarantees a structurally expanding addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry for cardiovascular, neurological, and urological interventions. Because these procedures are non-discretionary and clinically essential, demand remains entirely insulated from macroeconomic downturns, stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, and consumer spending retrenchment. This biological inevitability provides a highly predictable, long-term volume floor for the company's core product lines. |
| Pulsed Field Ablation S-Curve Inflections curve inflectionThe point where adoption shifts from slow early growth to rapid expansion, or begins to mature.View full glossary entry | Innovation And Product | +25% | +20% | The transition from legacy thermal ablation to Pulsed Field Ablation (PFA) represents a major technological paradigm shift in treating atrial fibrillation. As the early-mover leader with its flagship platform, the company is experiencing rapid clinical adoption and global expansion. This high-margin procedural shift drives substantial volume growth and market share gains, offsetting legacy segment deceleration. |
| Value-Accretive Capital Allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry | Capital Allocation | +20% | +15% | Management is actively weaponizing its robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry engine to execute aggressive share repurchases at distressed valuationdistressed valuationA depressed valuation level caused by high perceived risk, weak confidence, or financial stress.View full glossary entry levels. By retiring undervalued equity, the company mathematically accelerates per-share earnings growth. Additionally, strategic acquisitions in high-growth adjacencies like neurovascular care expand the competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry and secure long-term terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry. |
| Elite Gross Margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and Pricing Powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry | Operational Efficiency | +18% | +15% | Operating with gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near seventy percent, the company possesses exceptional pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and structural insulation against inflationary pressures. The high value-density of its medical devices allows the firm to successfully pass through raw material and logistics cost increases to hospital networks, ensuring robust cash conversion and operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry defense. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Competitive Encroachment in Electrophysiology | Competitive Positioning | -18% | -12% | The company's early-mover monopoly in Pulsed Field Ablation is facing intense competition as major medical technology peers launch rival platforms. This competitive convergence threatens to dilute market share, introduce pricing pressure, and force elevated marketing and commercial spending to defend the installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry, structurally dragging on segment margins. |
| Debt Absorption and Integration Risks | Capital Allocation | -15% | -10% | Executing multiple large-scale acquisitions has significantly elevated the company's debt loaddebt loadSignificant financial burden requiring constant cash flow to maintain solvency and service interest.View full glossary entry and leverage profile. In a higher-for-longer interest rate environment, servicing this debt increases interest expenses and restricts near-term capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry flexibility. Furthermore, digesting several massive corporate integrations concurrently introduces execution and distraction risks. |
| Hospital Capital Expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry Constraints | Macroeconomic And Macrofinancial | -12% | -8.0% | Strained hospital operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry, driven by persistent labor shortages and utility inflation, are forcing healthcare administrators to implement strict capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry freezes. While the company's consumables are highly insulated, delayed replacement cycles for high-cost capital equipment and mapping systems could temporarily slow new platform installations. |
| Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry and Input Cost Inflation | Operational Efficiency | -10% | -6.0% | Geopolitical disruptions and energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry have triggered acute shortages and cost spikes in critical manufacturing inputs, such as medical-grade plastics, packaging resins, and helium. Although the company's high gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry provide a buffer, the inherent lag in renegotiating hospital contracts temporarily compresses near-term operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Class I FDA Recall or Safety Failure | 15% | -35% | Regulatory | A systemic safety failure or unexpected adverse events in a flagship cardiovascular or electrophysiology device could trigger a Class I FDA recall. This would severely damage physician trust, invite multi-billion dollar legal liabilities, and permanently impair the company's core growth engine and terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry. |
| Severe Electrophysiology Price Warprice warIntense competitive price cutting that can reduce industry margins and alter market share.View full glossary entry | 20% | -25% | Competitive Positioning | If major competitors aggressively discount their rival pulsed field ablation systems to capture market share, the industry could devolve into a commoditized price warprice warIntense competitive price cutting that can reduce industry margins and alter market share.View full glossary entry. This would force the company to slash premium pricing, fracturing its high-margin consumables model and permanently compressing free cash flow marginsfree cash flow marginsThe percentage of revenue converted into cash after accounting for capital expenditures and operating costs.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Expanded Clinical Indications Approval | 35% | +20% | Regulatory | Securing expanded regulatory approvals for flagship devices, such as first-line therapy indications for left atrial appendage closure, would dramatically expand the addressable patient pool. This breakthrough would trigger immediate upward earnings revisions and re-rate the stock as an uncontested market leader. |
| Accelerated M&A Synergy Capture | 30% | +15% | Capital Allocation | If the integration of recent large-scale neurovascular acquisitions executes flawlessly ahead of schedule, the company could realize massive cross-selling synergiescross selling synergiesAdditional revenue expected from selling more products or services to the combined customer base after a transaction.View full glossary entry through its global distribution network. Rapidly deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry and proving immediate earnings accretion would dismantle the over-leveraged narrative and drive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
Company Financial Analysis
Boston Scientific Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's financial performance shows a strong contrast between its actual business results and its stock price. While the stock has dropped due to lowered growth forecasts, the company's actual earnings remain incredibly strong. In recent quarters, sales have grown by double digits, and net income has surged dramatically. The business is highly efficient at turning its sales into pure cash, generating over three billion dollars in free cash flow. Most reports agree that this massive cash generation provides a strong safety net during tough economic times. However, there is some disagreement on how quickly the company can grow in the near term as it works to pay down debt from recent acquisitions. Overall, the financial health of the company is highly robust, making the recent stock drop look like a temporary disconnect from its strong cash-printing reality.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 20.1B | USD 2.9B | USD 3.7B |
| 2024 | USD 16.7B | USD 1.9B | USD 2.6B |
| 2023 | USD 14.2B | USD 1.6B | USD 1.7B |
| 2022 | USD 12.7B | USD 698M | USD 914M |
| 2021 | USD 11.9B | USD 1B | USD 1.3B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 49.4x | TTM | Native | USD / USD |
| 2024 | 71.8x | TTM | Native | USD / USD |
| 2023 | 53.6x | TTM | Native | USD / USD |
| 2022 | 95.6x | Annual | Native | USD / USD |
| 2021 | 58.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company boasts incredible profitability, with gross margins near seventy percent. This means that for every dollar of product sold, seventy cents is left over to cover operating costs and generate profit. This high margin gives the company immense pricing power, allowing it to pass rising costs from inflation and shipping directly to hospitals. Reports agree that these strong margins are protected by the unique, life-saving nature of the company's medical devices. However, there is some disagreement about the future direction of these margins. Some analysts worry that new competition in key heart-treatment markets will force the company to lower its prices, squeezing profits. Others believe that integrating higher-margin software and artificial intelligence into its devices will actually push profit margins even higher. Despite these differing views, the company's current profitability remains among the best in the healthcare industry.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 4B | 19.8% | 14.4% |
| 2024 | USD 2.6B | 15.7% | 11.1% |
| 2023 | USD 2.2B | 15.3% | 11.2% |
| 2022 | USD 1.8B | 14.4% | 5.5% |
| 2021 | USD 1.9B | 16.2% | 8.7% |
Balance sheet and leverage
The company's balance sheet has historically been an absolute fortress, with low debt and plenty of cash on hand. However, it recently took on significant new debt to fund a massive fourteen-billion-dollar acquisition. This has temporarily increased its leverage and made it more sensitive to high interest rates. Despite this increase in debt, reports strongly agree that the company's financial safety is not in danger. The business generates so much free cash flow that it can easily cover its interest payments and pay down its debt quickly. Some analysts worry that this new debt limits the company's ability to make more purchases or buy back its own stock in the near future. Others view the debt as a worthwhile trade-off to secure a dominant position in a highly profitable medical market. Overall, the balance sheet remains highly secure with excellent downside protection.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 12.4B | USD 2B | USD 10.4B net debt | 1.62x |
| 2024 | USD 11.1B | USD 414M | USD 10.7B net debt | 1.08x |
| 2023 | USD 9.5B | USD 865M | USD 8.6B net debt | 1.32x |
| 2022 | USD 9.3B | USD 928M | USD 8.4B net debt | 1.51x |
| 2021 | USD 9.5B | USD 1.9B | USD 7.5B net debt | 1.48x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is highly efficient with its spending, requiring very little money to maintain its daily operations. It spends only about four percent of its revenue on physical buildings and equipment, which is very low for a manufacturer. Instead, the company focuses its financial power on research and development to create new, patent-protected medical devices, and on buying other successful healthcare companies. Reports agree that this strategy helps the company stay ahead of competitors without wasting cash. However, opinions differ on whether the company is spending too much on buying other businesses right now. Some believe these purchases are smart moves to secure future growth, while others worry that the heavy spending might temporarily lower the company's overall returns. Ultimately, the company's ability to fund all of its investments using its own cash, rather than borrowing expensive money, is a major strength.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 876M | USD 2.1B |
| 2024 | USD 790M | USD 1.6B |
| 2023 | USD 800M | USD 1.4B |
| 2022 | USD 612M | USD 1.3B |
| 2021 | USD 554M | USD 1.2B |
Quarterly Forecast Scenarios
Boston Scientific Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $43.33 | $46.98 | $51.91 | $736.09 | |
| $42.03 | $49.38 | $57.10 | $724.14 | |
| $42.88 | $51.63 | $61.67 | $713.57 | |
| $44.16 | $53.69 | $65.99 | $723.38 | |
| $43.28 | $55.34 | $69.29 | $716.61 | |
| $45.01 | $57.98 | $73.44 | $738.34 | |
| $46.36 | $60.23 | $77.12 | $746.91 | |
| $44.97 | $62.50 | $81.74 | $771.93 | |
| $47.22 | $64.88 | $85.01 | $782.73 | |
| $49.11 | $66.92 | $89.26 | $807.31 | |
| $50.58 | $68.82 | $92.83 | $822.72 | |
| $52.60 | $71.32 | $95.62 | $846.10 | |
| $53.65 | $72.73 | $91.79 | $852.53 | |
| $55.26 | $75.70 | $97.30 | $882.91 | |
| $54.16 | $77.92 | $100.22 | $900.46 | |
| $55.24 | $80.14 | $102.23 | $922.67 | |
| $56.90 | $82.21 | $105.29 | $935.91 | |
| $58.04 | $85.35 | $109.50 | $952.30 | |
| $57.46 | $87.57 | $111.69 | $976.28 | |
| $58.61 | $90.73 | $115.04 | $1,002 |
Research Provenance
References & Context
This Boston Scientific consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Sources retained from AI Researcher searches
Showing the top 1 of 1 deduplicated sources retained for this batch.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- 01bnnbloomberg.cabnnbloomberg.ca
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).